all_success_response = (
    '{"data": [{"Recommendation": "#1: Monitor glucose, HbA1c, blood pressure, body weight, lipid '
    "profile, and renal and liver function every 3 months.  #2: Consider screening patients with "
    "type 1 diabetes for autoimmune thyroid disease and celiac disease soon after diagnosis.  "
    "#3: In people with a history of cognitive impairment/dementia, intensive glucose control "
    "cannot be expected to remediate deficits. Treatment should be tailored to avoid significant "
    "hypoglycemia.  #4: In men with diabetes who have symptoms or signs of hypogonadism such as "
    "decreased sexual desire (libido) or activity, or erectile dysfunction, consider screening with "
    "a morning serum testosterone level.  #5: Screen for anxiety, depression, and disordered eating. "
    "Annually screen people who are prescribed atypical antipsychotic medications for prediabetes "
    'or diabetes.  #6: Annual dilated and comprehensive eye examination.","Optional/applicable '
    'conditions": "Diabetes","References": "American Diabetes Association"}, {"Recommendation": '
    '"American Diabetes Association recommends a hemoglobin A1c level of less than 7.0%, preprandial '
    "glucose values of 70 to 130 mg/dL (3.9-7.2 mmol/L), and 1- to 2-hour postprandial glucose values "
    "of less than 180 mg/dL (10 mmol/L). They also go on to recommend, Less stringent A1C goals "
    "(such as <8%) may be appropriate for patients with a history of severe hypoglycemia, limited "
    "life expectancy, advanced microvascular or macrovascular complications, extensive comorbid "
    "conditions, or long-standing diabetes in whom the goal is difficult to achieve. And the "
    "American College of Physicians recommends less intensive glucose control in most cases of "
    "type 2 diabetes, saying that targeting A1c levels below 7% may increase risk for death, "
    'weight gain, hypoglycemia, and other adverse effects.","Optional/applicable conditions": '
    '"Diabetes","References": "1. American Diabetes Association Diabetes Care 2018 Jan; '
    "41(Supplement 1).  2. Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; "
    "Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c Targets "
    "for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes "
    "Mellitus: A Guidance Statement Update From the American College of Physicians. Ann Intern "
    'Med. 2018. PMID: 29507945 doi:10.7326/M17-0939"},{"Recommendation": "For BMI greater than or '
    "equal to 35 with obesity-related conditions (diabetes, hypertension, sleep apnea, fatty liver, "
    "cholesterol problems, GI disorders, heart disease), consider bariatric surgery, such as "
    'laparoscopic adjustable gastric banding or sleeve gastrectomy.","Optional/applicable conditions": '
    '"Diabetes, Overweight or Obesity, Liver disease, Chronic heart disease, Chronic lung disease, '
    'Hypertension","References": "Jensen MD, Ryan DH, Apovian CM, et al; American College of '
    'Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society."},'
    '{"Recommendation": "For BMI greater than or equal to 27 with obesity-related conditions (diabetes, '
    "hypertension, sleep apnea, fatty liver, cholesterol problems, GI disorders, heart disease), or "
    "BMI of 30+ without those conditions, can consider pharmacologic treatment with Orlistat or "
    'Lorcaserin.","Optional/applicable conditions": "Diabetes, Overweight or Obesity, Liver disease, '
    'Chronic heart disease, Chronic lung disease, Hypertension","References": "Jensen MD, Ryan DH, '
    "Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on "
    'Practice Guidelines; Obesity Society."},{"Recommendation": "In very high-risk ASCVD patients, '
    "it is reasonable to add ezetimibe to maximally tolerated statin therapy when the LDL level "
    "remains ≥70 mg/dL (≥1.8 mmol/L). In patients at very high risk whose LDL level remains ≥70 "
    "mg/dL (≥1.8 mmol/L) on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 "
    "inhibitor is reasonable. Repeat lipid measurement 4 to 12 weeks after statin initiation or "
    'dose adjustment, repeated every 3 to 12 months as needed.","Optional/applicable conditions": '
    '"Congestive Heart Failure, Chronic heart disease","References": "American College of '
    'Cardiology/AHA, 2018 Guideline on the Management of Blood Cholesterol"}],"meta": {"status": '
    '"success", "totalResults": 5,"path": "https://getguidelines.com/all"}}'
)

vac_success_response = "{}"
